Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of ...
Agreement Reached on Primary Endpoint and Phase 3 Trial DesignOral APX3330 is a Late-Stage Clinical Asset Available for PartneringFARMINGTON ...